1.58
0.00 (0.00%)
| Previous Close | 1.58 |
| Open | 1.59 |
| Volume | 278,774 |
| Avg. Volume (3M) | 532,711 |
| Market Cap | 34,553,800 |
| Price / Sales | 14.87 |
| 52 Weeks Range | |
| Earnings Date | 26 Mar 2026 |
| Operating Margin (TTM) | -6,011.31% |
| Diluted EPS (TTM) | -11.12 |
| Quarterly Revenue Growth (YOY) | -71.10% |
| Current Ratio (MRQ) | 1.48 |
| Operating Cash Flow (TTM) | -66.36 M |
| Levered Free Cash Flow (TTM) | -48.95 M |
| Return on Assets (TTM) | -52.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BioXcel Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -1.13 |
|
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 8.65% |
| % Held by Institutions | 11.02% |
| 52 Weeks Range | ||
| Median | 6.00 (279.75%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 05 Mar 2026 | 6.00 (279.75%) | Buy | 1.61 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MEHTA VIMAL | - | - | 0 | 0 |
| RODRIGUEZ JAVIER | - | - | 0 | 0 |
| STEINHART RICHARD I | - | - | 0 | 0 |
| YOCCA FRANK | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| YOCCA FRANK | Officer | 15 Mar 2026 | Option execute | 35 | - | - |
| RODRIGUEZ JAVIER | Officer | 15 Mar 2026 | Option execute | 35 | - | - |
| STEINHART RICHARD I | Officer | 15 Mar 2026 | Option execute | 35 | - | - |
| MEHTA VIMAL | Officer | 15 Mar 2026 | Option execute | 219 | - | - |
| YOCCA FRANK | Officer | 14 Mar 2026 | Option execute | 33 | - | - |
| RODRIGUEZ JAVIER | Officer | 14 Mar 2026 | Option execute | 33 | - | - |
| STEINHART RICHARD I | Officer | 14 Mar 2026 | Option execute | 33 | - | - |
| MEHTA VIMAL | Officer | 14 Mar 2026 | Option execute | 164 | - | - |
| Date | Type | Details |
|---|---|---|
| 20 Jan 2026 | Announcement | BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting |
| 12 Jan 2026 | Announcement | BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting |
| 07 Jan 2026 | Announcement | BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI® |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |